Top news of the week: 01.09.2021.
Companies And Industries
Novel “scArches” Algorithm Maps Single-Cell Data to Reference Atlases
A novel deep learning strategy, single-cell architectural surgery (scArches), compares new datasets from single-cell genomics with existing references.
Korean Pharma's Phase III COVID Trial Will Compare Candidate to AZ Vaccine
The trial will enroll about 4,000 people worldwide to confirm the drug's safety and immunogenicity profiles.
Drug delivery capsule could replace injections for protein drugs
Researchers have developed a capsule that can carry large protein drugs, such as monoclonal antibodies, and inject them directly into the lining of the stomach.
GSK, Korean biotech SK go head-to-head against AstraZeneca's COVID-19 shot with their experimental vaccine
GlaxoSmithKline has been a little late to the COVID vaccine game and stumbled with partner Sanofi on the way, but it’s now hoping to rival and maybe even beat out AstraZeneca’s vaccine as ...
Feng Zhang's lab develops potential breakthrough in RNA editing delivery using 'ultracompact' versions of Cas13
As one of the pioneers behind CRISPR, the Broad Institute's Feng Zhang has fashioned himself into a gene editing Renaissance man in recent years with a finger in every pie. For RNA editing, ...
Neurogastrx assembles ex-Ironwood team with $60M to take on jam-packed gastrointestinal market
Neurogastrx is attempting to go up against a long-standing class of GERD drugs and others in the gastrointestinal disorder space. The biotech now has $60 million to bankroll a phase 3 study ...
Versanis Bio snags $70M for a ditched Novartis muscle drug, with a little help from its old CEO Joe Jimenez
Versanis Bio emerged with a $70 million series A to test a former failed Novartis drug in a phase 2 study for obesity. Backing the biotech is former Novartis CEO Joe Jimenez, who was in the ...
JHL Co-founders Convicted of Trade Secret Theft
Two former executives of JHL Biotech were indicted on charges of orchestrating the theft of trade secrets, wire fraud exceeding $101 million, and money laundering.